The level of the fatty acid translocase CD36 is increased on the plasma membrane of hepatocytes of MASH patients, while inhibition of CD36 palmitoylation ameliorates intracellular lipid accumulation, providing a viable therapeutic strategy for the treatment of MASLD [27]. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatohepatitis.